CS
JANX icon

Credit Suisse’s Janux Therapeutics JANX Stock Holding History

Credit Suisse’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$729K Buy
19,361
+1,051
+6% +$22.9K ﹤0.01% 2452
2023
Q4 		$196K Buy
18,310
+2,595
+17% +$22.4K ﹤0.01% 2988
2023
Q3 		$158K Sell
15,715
-184
-1% -$2.12K ﹤0.01% 3063
2023
Q2 		$189K Buy
+15,899
New +$213K ﹤0.01% 3101
2023
Q1 		– Sell
-1
Closed -$13 – 3516
2022
Q4 		$13 Sell
1
-93
-99% -$1.36K ﹤0.01% 3701
2022
Q3 		$1K Buy
94
+77
+453% +$1.03K ﹤0.01% 3870
2022
Q2 		$0 Buy
+17
New +$201 ﹤0.01% 4124

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Credit Suisse's JANX Position: Q1 2024 in Review

Credit Suisse increased its Janux Therapeutics (JANX) stake by 5.7% in Q1 2024, buying an estimated $22.9K and bringing the position to 19,361 shares worth $729K. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

Credit Suisse first reported a position in JANX in Q2 2022 and has held it in 7 quarters since. 121 funds tracked by Wall St. Rank hold JANX as of Q1 2024.

  • Credit Suisse held 19,361 shares of Janux Therapeutics worth $729K as of Q1 2024.
  • Credit Suisse bought 1,051 Janux Therapeutics shares in Q1 2024, an estimated $22.9K.
  • Janux Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2452 holding.
  • Credit Suisse first reported a position in Janux Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • 121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.